ACR 2022 Tweet by Eric Dein
Tweet
Related Content
The New England Journal of Medicine has published a phase III clinical trial showing that a B cell targeting monoclonal antibody, ianalumab, was effective in more than half of the patients with primary immune thrombocytopenia (ITP). Moreover, treatment maintained safe platelet counts…
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.Modest Benefits with AI Scribes on EHR Documentation Documenting patient visits in the EHR is essential to care, but a major contributor to clinician burnout. AI-enabled ambient documentation (“AI scribes”) can…
Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) often overlap. While there have been some therapeutic advances, significant needs remain around diagnosis and monitoring, with a gap around definitions and biomarkers for refractory disease or specific subsets. EULAR – The…
